Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a report published on Friday,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent BioSolutions’ Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Price Performance

EBS stock opened at $5.70 on Friday. Emergent BioSolutions has a 12 month low of $1.82 and a 12 month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a 50-day moving average price of $8.48 and a 200 day moving average price of $8.73. The stock has a market cap of $309.45 million, a PE ratio of -1.39 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. During the same period in the previous year, the company earned ($0.77) EPS. Equities research analysts anticipate that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Insider Activity at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now owns 101,100 shares in the company, valued at approximately $589,413. The trade was a 25.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Emergent BioSolutions

Large investors have recently modified their holdings of the business. Covestor Ltd raised its holdings in shares of Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Emergent BioSolutions in the 4th quarter valued at about $63,000. E Fund Management Co. Ltd. bought a new stake in shares of Emergent BioSolutions in the 4th quarter valued at about $98,000. EP Wealth Advisors LLC bought a new stake in shares of Emergent BioSolutions in the 4th quarter valued at about $110,000. Finally, Stifel Financial Corp bought a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $96,000. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.